Simplify Logo
Jazz Pharmaceuticals

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

KOL & External Engagement Platforms Senior Manager - Global Capability Owner

Full-Time
$140.8k - $211.2k/yr

+ Bonus + Equity Grants

Senior
Bachelor's, MBA
Pennsylvania, USA
Remote

Remote within the United States; 20-30% travel.

About the job

Requirements
  • Bachelor’s degree in business, technology, marketing, science, or related field.
  • 6+ years of experience in pharmaceutical, healthcare, or other highly regulated industries
  • Experience in digital product management, product ownership, or demonstrated experience managing the creation and delivery of a product roadmap within a cross-functional team.
  • Experience working with event and engagement management platforms, engagement tools, and vendor-supported engagement solutions.
  • 20 to 30% travel will be required.
Responsibilities
  • Define the product vision and outcomes aligned to global and franchise priorities in collaboration with key stakeholders ensuring platforms strengthen Jazz’s credibility with the medical community.
  • Lead the ongoing evolution of the KOL & External Engagement Platforms roadmap, making prioritization and trade-off decisions to add the most value based upon objective data and user feedback.
  • Translate business needs into product solutions with measurable success metrics that drive impact across franchises and the business.
  • Drive delivery of a global roadmap that sequences platform governance, workflow improvements, and engagement capability enhancements across the Customer Engagement Platform (Patient, Caregiver, HCP, Healthcare Organizations), and related tools to improve execution efficiency, event performance tracking, and compliant KOL engagement at scale.
  • Connect business stakeholders (e.g., franchises, regions, finance, contracting) with the KOL & External Engagement Platforms global capability team, ensuring requirements are clearly defined and aligned to strategically important business outcomes and success metrics.
  • Partner closely with the Global Capability Owner and Tech Leads to align business priorities with technical feasibility and delivery sequencing, ensuring trade-offs support agreed business outcomes.
  • Partner closely with the Suite Lead to align product priorities, scope and roadmap decisions with team-level business objectives, ensuring consistent focus on enterprise outcomes and value delivery.
  • Define clear product requirements, user stories, and acceptance criteria to enable efficient execution and alignment with business partner activity needs.
  • Partner across the Customer Experience Organization to support seamless integration and ongoing product evolution to support scalability, flexibility, and compliance requirements
  • Drive more impactful engagement and measurable outcomes by enabling scalable planning, execution, and measurement of external activities and programs.
  • Design scalable approach to KOL identification, end-to-end co-creation workflow and annual planning, aligning systems and tools to facilitate a global approach.
  • Apply user insights and engagement data to inform the design and evolution of KOL & External Engagement Platform capabilities that enhance the customer experience for both internal and external users.
  • Participate in and support discovery efforts, engaging directly with users and key stakeholders to deeply understand their needs, validate business value, and assess technical feasibility prior to development
  • Partner across Global Capability product teams to deliver scalable, reusable KOL & External Engagement Platforms capabilities.
  • Monitor product adoption, outcome KPIs and engagement metrics to inform backlog prioritization and continuous improvement.
  • Manage documentation of (PRDs, user stories, discovery artifacts), and sprint planning in partnership with the Tech Lead and development teams.
  • Contribute to experimentation to improve Customer Engagement Platform (Patient, Caregiver, HCP, Healthcare Organizations) outcomes.
  • Leverage outcome metrics to articulate the product's value proposition and its impact, promoting product awareness across CX operations and foster a culture of engagement and feedback in partnership with Activation.
Desired Qualifications
  • Advanced degree (MBA or relevant graduate degree) preferred.
  • Experience working in a product operating model.
  • Experience partnering with Product teams supporting digital and operational capabilities.
  • Advanced degrees may offset a portion of required years of experience, consistent with global hiring guidelines.
  • Experience working in rare disease or specialty brands, with strong understanding of unique stakeholder dynamics.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ziihera's August 2026 FDA win expands Jazz into a $3 billion-to-$5 billion opportunity.
  • Q2 2026 revenue reached $1.21 billion, and guidance rose to $4.60 billion-$4.75 billion.
  • Actio Biosciences acquisition closed September 15, 2026, adding KCNT1+ epilepsy upside.

What critics are saying

  • Tris Pharma filed generic Xywav and Xyrem applications in January 2026, threatening 2027 pricing.
  • Long-term debt was $4.4 billion at June 30, 2026, limiting flexibility for pipeline deals.
  • Zepzelca's failed second-line SCLC trial narrows growth if first-line maintenance adoption slows.

What makes Jazz Pharmaceuticals unique

  • Xywav's low-sodium profile keeps narcolepsy and idiopathic hypersomnia patients on therapy.
  • Ziihera became Jazz's first FDA-approved HER2-targeted backbone for first-line GEA on August 25, 2026.
  • Jazz combines rare sleep, epilepsy, and oncology commercialization across one scaled specialty platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.